Is Oracle A Screaming Buy?

Oracle Corporation (NASDAQ:ORCL) was one of the most popular technology stocks among hedge funds and other notable investors during the second quarter of 2012, according to our database of 13F filings (see the full list of the most popular technology stocks). Seth Klarman’s Baupost Group initiated a position of nearly 16 million shares in Oracle between April and June; this made it the third largest holding by market value in the fund’s 13F portfolio (find more of Seth Klarman’s stock picks). Oracle was also one of billionaire Ken Fisher’s favorite stocks, as his Fisher Asset Management reported a position of 20 million shares at the end of the quarter (research more stocks that Fisher Asset Management owned). The database software and management company’s stock price is up 20% on the year, edging the return of the NASDAQ index.

BAUPOST GROUP

In Oracle Corporation’s most recent fiscal quarter (the first of its fiscal year; the quarter ended in August), revenues were down 2% from the first fiscal quarter of last year. Growth in software- the company’s largest source of sales- was offset by a decline in hardware systems. However, an impressive cost-cutting program has brought operating expenses down 7% over the same period, and that includes a 14% increase in research and development (which could be considered a good investment for a technology company). With share count down as well (about $3 billion was used to buy back stock in the quarter), earnings per share for the third quarter of 2012 were 41 cents, up from 36 cents in Q3 2011.

Perhaps surprisingly given its successful business performance and its market capitalization of nearly $150 billion, Oracle Corporation only trades at 15 times trailing earnings. We think that this is too low for what we see at the company. Sell-side analysts expect continued earnings growth at the company, both in 2013 and over the next several years: their consensus estimates imply a forward P/E multiple of 11 and a five-year PEG ratio of 1.

Large enterprise software companies such as Microsoft Corporation (NASDAQ:MSFT), International Business Machines Corp. (NYSE:IBM), SAP AG (NYSE:SAP), and salesforce.com, inc. (NYSE:CRM) make good peers for Oracle. salesforce.com has fairly low net income in comparison to its stock price, and trades at 74 times forward earnings estimates even with Wall Street consensus showing considerable earnings growth in the next year. About 13% of the shares outstanding are held short, and while we’d be careful to go short such a fast growing company (revenue was up 34% last quarter versus a year earlier) we don’t think that it’s a good buy either. SAP also looks expensive, with trailing and forward P/E multiples close to 20. Its earnings were down sharply in the third quarter compared to the third quarter of 2011 as well; even with good top-line numbers, we’d avoid the stock.

IBM seems to have done well at transitioning somewhat from hardware to software- its earnings were flat in its most recent quarter compared to the same point in the previous year, a much better result than what we have been seeing at many hardware companies- yet the market does not look very optimistic about the stock. It trades at 14 times trailing earnings, a slight discount to Oracle. Its forward P/E is also close to where that company is valued. Given that Oracle is seeing better earnings growth, possibly because its software/services/hardware mix is still more favorable, we would prefer it. Our attitude towards Microsoft can be characterized as “wait and see.” Its forward P/E of 9 is appealing, but we know that at least some of that pricing is due to the expectation that the company will see a temporary bump to its business as consumers buy the new versions of Windows and Office. With Windows 8 and Surface both serving as potential minefields for the company, we’d be prepared to buy Microsoft if the stock takes a dive upon any bad news.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!